Expertise in
4
conditions

Andrea Kundgen

Duesseldorf, NW, DE 
Expertise in
4
conditions
Duesseldorf, NW, DE 

Overview

Andrea Kundgen practices practicing medicine in Duesseldorf, Germany.

Ms. Kundgen is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Duesseldorf, NW 40225, Germany
Other Locations
Munich, BY, Germany
Heine, NW, Germany
Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

83 Total Publications

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.
Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.
Journal: Annals of hematology
Published: May 15, 2026

Frequently Asked Questions about Andrea Kundgen

Is Andrea Kundgen a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Andrea Kundgen is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andrea Kundgen participate in research or clinical trials?

Yes. Andrea Kundgen has published 83 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Andrea Kundgen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kundgen's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile